Role of Ron kinase in pancreatic cancer
Ron 激酶在胰腺癌中的作用
基本信息
- 批准号:8245577
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenocarcinoma CellAffectAttenuatedAwardBindingBreast Cancer CellCD44 geneCancer EtiologyCancer cell lineCellsCessation of lifeClinical TrialsDNADataDevelopmentDiagnosisDiseaseEpithelial CellsEventFellowship ProgramFunctional disorderFundingGenesGeneticGenetic TranscriptionGoalsGrowthHIF1A geneHealthcareHospitalsHypoxiaIn VitroInvestigationKnock-outKnowledgeLeadLengthLesion by StageLigandsLinkMalignant neoplasm of pancreasMediatingMedical OncologyMolecular TargetMutationNeoplasm MetastasisNull LymphocytesOncogenicOncology GroupPancreasPancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPhosphotransferasesPhysiciansPlayPopulationPropertyRadiation therapyRegulator GenesReportingResearch Project GrantsResistanceRoleScientistSignal PathwaySignal TransductionSolid NeoplasmSurvival RateSystemTestingTherapeuticTimeTrainingTranscription CoactivatorTranscriptional ActivationTransforming Growth Factor betaTranslational ResearchTumor Cell InvasionTumor PromotersTumor Suppressor ProteinsTumor-DerivedUp-RegulationVeteransattenuationbasecancer stem cellcell growthchemotherapyenzyme pathwaygene repressionimprovedin vivoinhibitor/antagonistkinase inhibitorknock-downmolecular oncologymortalityneoplastic cellnovel strategiesoutcome forecastpatient populationpreclinical studypreventprogramspromoterpublic health relevancereceptorstem cell populationtherapeutic targettherapy resistanttranscription factortumortumor growthtumor progression
项目摘要
DESCRIPTION (provided by applicant):
Pancreatic ductal adenocarcinomas (PDAC) continue to have the worst prognosis of all solid tumors with a five-year survival of less than 5%. The high mortality rate from PDAC is mainly caused by widepread invasive and metastatic disease at the time of diagnosis and general resistance to chemotherapy. Biologically targeted therapies are under investigation with the hope of improving survival of patients with PDAC. To date these therapies provide very modest increase in survival length with no increase in overall survival. Currently gaps exist between known genetic alterations that give rise to PDAC with how these alterations impact critical signaling pathways and networks that mediate invasiveness and chemoresistance. Our preliminary data details the discovery of a dynamic cross talk between Ron kinase and Smad-independent TGF2 signaling that promotes tumor growth, invasion and metastasis. Moreover, we demonstrate that Ron is not aberrantly expressed in the cancer stem cell population but is induced during tumor progression as a result of loss or attenuation of Smad signaling and through transcriptional activation in part through HIF-11. Based on these findings we hypothesize that the TGF2/RON axis plays an important role in progression of PDAC and that understanding the interactions of these pathways will lead to novel strategies for improving therapy. To test this hypothesis we propose three specific aims: Objective 1. Determine the functional role of Ron/TGF2 axis in the development and progression of PDAC. Objective 2. Determine the mechanism(s) that causes aberrant up regulation of Ron in PDAC and whether Ron is differentially expressed in an invasive but non cancer stem cell population. Objective 3. Determine whether targeting the Ron/TGFb axis improves therapy of PDAC. The studies proposed in the current application will investigate the role that interaction of TGF2 and RON kinase play in the invasive properties of PDAC with the premise that this knowledge will contribute to new approaches for therapy. The proposed studies will be conducted as part of the clinical trials and translational research program at the Audie Murphy VA-Hospital for which the PI, Dr. James Freeman, directs the molecular oncology group. The goal of this pre-clinical study is to provide the bases for clinical trials in the VA population with the aim of improving survival of VA patients that present with PDAC. A further impact that this award will have on veterans health care is that this research project is integrated with the medical oncology fellowship program and therefore offers an excellent training venue for candidates seeking to become physician-scientist in the VA system.
PUBLIC HEALTH RELEVANCE:
Pancreatic cancer (PDAC) is the fourth leading cause of cancer deaths in the VA patient population with a median survival rate of less than 5%. PDAC are highly resistant to chemo- and radiation therapy. Present therapy includes inhibiting aberrantly expressed enzymes and pathways that play a role in tumor progression. However, gaps exist between known genetic alterations that give rise to PDAC with how these alterations impact critical signaling pathways that mediate invasiveness and resistance to therapy. We recently found that the interaction of Ron kinase and TGF2 play an important role in the progression of PDAC. Studies proposed in the current application will investigate the mechanisms by which Ron Kinase and TGF2 promote the invasion of PDAC. The knowledge gained from these studies will hopefully contribute to new approaches for therapy.
描述(由申请人提供):
胰腺导管腺癌(PDAC)仍然是所有实体瘤中预后最差的,5年生存率低于5%。PDAC的高死亡率主要是由于诊断时广泛的浸润和转移性疾病以及对化疗的普遍耐药。生物靶向治疗正在研究中,希望能提高PDAC患者的生存率。迄今为止,这些疗法提供了非常适度的生存期延长,而没有增加总生存期。目前,已知的引起PDAC的遗传改变与这些改变如何影响介导侵袭性和耐药性的关键信号通路和网络之间存在差距。我们的初步数据详细说明了罗恩激酶和Smad非依赖性TGF 2信号之间的动态串扰的发现,促进肿瘤生长,侵袭和转移。此外,我们证明,罗恩不是异常表达的癌症干细胞群体,但在肿瘤进展过程中诱导的结果损失或衰减的Smad信号转导和通过转录激活,部分通过HIF-11。基于这些发现,我们假设TGF 2/罗恩轴在PDAC的进展中起重要作用,并且理解这些途径的相互作用将导致改进治疗的新策略。为了验证这一假设,我们提出了三个具体目标:目标1。明确罗恩/TGF 2轴在PDAC发生发展中的功能作用。目标2.确定导致PDAC中罗恩异常上调的机制,以及罗恩是否在侵袭性但非癌症干细胞群体中差异表达。目标3.确定靶向罗恩/TGF β轴是否改善PDAC的治疗。本申请中提出的研究将研究TGF 2和罗恩激酶的相互作用在PDAC的侵袭性中所起的作用,前提是该知识将有助于新的治疗方法。拟定的研究将作为Audie Murphy VA医院临床试验和转化研究项目的一部分进行,PI James Freeman博士领导分子肿瘤学小组。本临床前研究的目的是为VA人群的临床试验提供基础,旨在改善患有PDAC的VA患者的生存率。该奖项将对退伍军人医疗保健的进一步影响是,该研究项目与医学肿瘤学奖学金计划相结合,因此为寻求成为VA系统中的医生科学家的候选人提供了一个很好的培训场所。
公共卫生关系:
胰腺癌(PDAC)是VA患者人群中癌症死亡的第四大原因,中位生存率低于5%。PDAC对化疗和放疗具有高度抵抗性。目前的治疗包括抑制在肿瘤进展中起作用的异常表达的酶和途径。然而,在引起PDAC的已知遗传改变与这些改变如何影响介导侵袭性和对治疗的抗性的关键信号通路之间存在差距。我们最近发现罗恩激酶和TGF-2的相互作用在PDAC的进展中起重要作用。本申请中提出的研究将调查罗恩激酶和TGF 2促进PDAC侵袭的机制。从这些研究中获得的知识有望有助于新的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James W. Freeman其他文献
Interdisciplinary collaboration within project-level NEPA teams in the US Forest Service
美国林务局项目级 NEPA 团队内的跨学科合作
- DOI:
10.1080/09640568.2010.525024 - 发表时间:
2011 - 期刊:
- 影响因子:0
- 作者:
James W. Freeman;M. Stern;M. Mortimer;D. Blahna;L. Cerveny - 通讯作者:
L. Cerveny
Nursing home performance under case-mix reimbursement: responding to heavy-care incentives and market changes.
案例组合报销下的疗养院绩效:应对重症护理激励和市场变化。
- DOI:
- 发表时间:
1998 - 期刊:
- 影响因子:3.4
- 作者:
Mark A. Davis;James W. Freeman;Eric C. Kirby - 通讯作者:
Eric C. Kirby
James W. Freeman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James W. Freeman', 18)}}的其他基金
Role of CD44 in adaptive plasticity of pancreatic cancer
CD44在胰腺癌适应性可塑性中的作用
- 批准号:
9339582 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Role of CD44 in adaptive plasticity of pancreatic cancer
CD44在胰腺癌适应性可塑性中的作用
- 批准号:
8925205 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Role of ErbB/Stat3 in the establishment and progression of pancreatic cancer
ErbB/Stat3 在胰腺癌发生和进展中的作用
- 批准号:
7422386 - 财政年份:2007
- 资助金额:
-- - 项目类别:
Role of ErbB/Stat3 in the establishment and progression of pancreatic cancer
ErbB/Stat3 在胰腺癌发生和进展中的作用
- 批准号:
7191970 - 财政年份:2007
- 资助金额:
-- - 项目类别:
Role of TGFB Receptor Alterations in Pancreatic Cancer
TGFB 受体改变在胰腺癌中的作用
- 批准号:
6579965 - 财政年份:1997
- 资助金额:
-- - 项目类别:
Role of TGFB Receptor Alterations in Pancreatic Cancer
TGFB 受体改变在胰腺癌中的作用
- 批准号:
6784589 - 财政年份:1997
- 资助金额:
-- - 项目类别:
相似海外基金
Assessing The Impact of Heparanase and NDST2 Expression on Non-Small Cell Lung Adenocarcinoma Cell Motility
评估乙酰肝素酶和 NDST2 表达对非小细胞肺腺癌细胞运动的影响
- 批准号:
449570 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Studentship Programs
Analysis of cancer metastasis and invasion mechanism using a new lung adenocarcinoma cell line.
使用新的肺腺癌细胞系分析癌症转移和侵袭机制。
- 批准号:
16K10689 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Acquisition strategy of tumor-specific markers using established micropapillary pattern pulmonary adenocarcinoma cell line
使用已建立的微乳头模式肺腺癌细胞系获取肿瘤特异性标志物的策略
- 批准号:
26460441 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
The antibetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
抗生素药物二甲双胍在体外和体内抑制食管腺癌细胞增殖。
- 批准号:
25860540 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Young Scientists (B)
The cell permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferations and can be used as the molecular targeting dru
细胞通透肽抑制胰腺导管腺癌细胞增殖,可作为分子靶向药物
- 批准号:
25461969 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic Research for elucidation of chemo-resistance in mucinous adenocarcinoma cell.
阐明粘液腺癌细胞化疗耐药性的基础研究。
- 批准号:
22791532 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Young Scientists (B)
TAS::75 0849::TAS IN THIS PHASE I SBIR THE BREAST CANCER ADENOCARCINOMA CELL LI
TAS::75 0849::TAS 在这一阶段 I SBIR 乳腺癌腺癌细胞 LI
- 批准号:
8164743 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Role of Endothelin-1 in osteoblastic bone metastasis produced by a human lung adenocarcinoma cell line
Endothelin-1 在人肺腺癌细胞系产生的成骨细胞骨转移中的作用
- 批准号:
19790127 - 财政年份:2007
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Young Scientists (B)
CONNEXIN 43 EXPRESSION IN ADENOCARCINOMA CELL LINE
连接蛋白 43 在腺癌细胞系中的表达
- 批准号:
6972483 - 财政年份:2004
- 资助金额:
-- - 项目类别:
The mechanisms of highly metastetic capasity in highly metastatic subpopulations of lung adenocarcinoma cell line and these clinical applications
肺腺癌细胞系高转移亚群的高转移能力机制及临床应用
- 批准号:
15590831 - 财政年份:2003
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)